Unable to display view head.php file not found.
 
American Journal of Medicine
 

ACCF/AHA/HRS Focused Update Recommendations for Dabigatran

US guidelines from the American College of Cardiology/American Heart Association/Heart Rhythm Society (ACCF/AHA/HRS)25]
have expressed no preferences between a NOAC – in this case dabigatran, when these guidelines were written – and a vitamin K antagonist (Figure 17).  The guideline specifies the patients for whom the therapy is recommended and specifically states that in patients with renal failure (creatinine clearance <15 mL/min), advanced liver disease, or with significant valve disease, vitamin K antagonists are preferable to dabigatran.  Camm J. Am J Med 2013; published on-line at http://education.amjmed.com/00000.

References

[25] Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2011;57:1330-1337.

Unable to display view foot.php file not found.